sitagliptin glp 1 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Sitagliptin - First In Class

Heinemann, B

Very high doses can result in psychosis, which rarely occurs at therapeutic doses even during long-term use

That constant nausea on day three after the injection might mean that your dose is too high

When a peripheral nerve fiber is damaged, the portion of the axon beyond the injury point degenerates through a process called Wallerian degeneration

The third concern relates to gastric emptying and absorption timing, which we will explore in dedicated detail in a later section

Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, et al Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: Improvement of fasting glycemia in diabetic db/db mice Mol Pharmacol